Filter Lifespan in Continuous Renal Replacement Therapy
The Effect of Filter Lifespan in Continuous Renal Replacement Therapy on the Rate of New Infections in Critically Ill Patients: a Prospective, Multicenter, Observational Trial
University Hospital Muenster
600 participants
Mar 2, 2023
OBSERVATIONAL
Conditions
Summary
The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.
Eligibility
Inclusion Criteria4
- Adult patients (age ≥18 years)
- Critically ill patients with dialysis-dependent AKI
- Continuous renal replacement therapy (CRRT)
- Written informed consent
Exclusion Criteria7
- Chronic kidney disease with estimated glomerular filtration rate (eGFR)<30ml/min/1.73m2
- Chronic dialysis dependency
- Kidney transplant
- (Glomerulo-)nephritis, interstitial nephritis, vasculitis
- Patients on immunosuppression
- Patients with chronic inflammatory diseases (e.g. arthritis, HIV, chronic hepatitis)
- Persons with any kind of dependency on the investigator or employed by the sponsor or investigator
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05450185